V.1.2014; Acute Myeloid Leukemia V.2.2014; Bladder Cancer V.2.2014; Chronic Myelogenous Leukemia V.3.2014; Hodgkin Lymphoma (V.2.2013); Multiple Myeloma (V.2.2014); Myeloid Growth Factors (V.2.2013); Systemic Light Chain Amyloidosis (V.2
Search Results
NCCN News
NCCN News
Myeloid Leukemia Bladder Cancer Breast Cancer Genetic/Familial High-Risk Assessment: Breast and Ovarian Genetic/Familial High-Risk Assessment: Colorectal Hodgkin Lymphoma Lung Cancer Screening Neuroendocrine Tumors Pancreatic Adenocarcinoma
NCCN News
People with Leukemia Better Understand Their Treatment Options NCCN has released a free booklet to empower people with acute myeloid leukemia (AML) and their loved ones with resources for better informed medical decision-making. The NCCN
NCCN News
leukemia (CLL), NHL, acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL), Castleman disease, classical Hodgkin lymphoma
NCCN News
different cancer types, some of which include acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), Hodgkin lymphoma, multiple myeloma (MM), and myeloproliferative neoplasms (MPN), as well as the management of bone
A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer
C. Anthony Blau, Arturo B. Ramirez, Sibel Blau, Colin C. Pritchard, Michael O. Dorschner, Stephen C. Schmechel, Timothy J. Martins, Elisabeth M. Mahen, Kimberly A. Burton, Vitalina M. Komashko, Amie J. Radenbaugh, Katy Dougherty, Anju Thomas, Christopher P. Miller, James Annis, Jonathan R. Fromm, Chaozhong Song, Elizabeth Chang, Kellie Howard, Sharon Austin, Rodney A. Schmidt, Michael L. Linenberger, Pamela S. Becker, Francis M. Senecal, Brigham H. Mecham, Su-In Lee, Anup Madan, Roy Ronen, Janusz Dutkowski, Shelly Heimfeld, Brent L. Wood, Jackie L. Stilwell, Eric P. Kaldjian, David Haussler, and Jingchun Zhu
compared in a high-throughput screen of 160 approved and investigational oncology drugs currently being tested in acute myeloid leukemia at UW ( ClinicalTrials.gov identifier: NCT01872819). CTC-enriched and CTC-depleted cell fractions were seeded into non
A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic
Joan How and Gabriela S. Hobbs
risk of acute myeloid leukemia transformation. Unlike prior models, the MPN Personalized Risk Calculator recognized TP53 mutations as a particularly poor prognostic feature. Although this tool requires further experience and validation, it represents
An Analysis of Hospital Costs for Childhood Cancer Care
Owen Tan, Deborah J. Schofield, and Rupendra Shrestha
Hematol Oncol 2005 ; 27 : 295 – 300 . 10.1097/01.mph.0000168724.19025.a4 15956880 32. Mahmoud D , Skikne BS , Kucmin-Bemelmans I , Overall economic burden of total treatment costs in acute myeloid leukemia throughout the course of
Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes
Eva Battaglini, David Goldstein, Peter Grimison, Susan McCullough, Phil Mendoza-Jones, and Susanna B. Park
breast cancer who received chemotherapy 5 and in 78% of 1,360 women with ovarian cancer 2.3 years since completing chemotherapy. 6 Similarly, 52% of 1,182 patients with acute myeloid leukemia reported CIPN 7.3 years postdiagnosis. 4 Furthermore, our
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Ruben Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Rebecca B. Klisovic, Patricia Kropf, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolai Podoltsev, Daniel A. Pollyea, Raajit Rampal, Lindsay A. M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, and Hema Sundar
, and PV in the United States is estimated to be approximately 13,000, 134,000 and 148,000, respectively. 1 MPNs are characterized by a complicated symptom profile and a risk of transformation to acute myeloid leukemia (AML), which is associated with a